Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jul 12;47(3):e20210230.
doi: 10.36416/1806-3756/e20210230.

The not so small role of adjuvant chemotherapy in resected non-small cell lung cancer

[Article in English, Portuguese]
Daniel R Almquist  1 , Panayiotis Savvides  1 , Vinicius Ernani  1
Affiliations
Editorial

The not so small role of adjuvant chemotherapy in resected non-small cell lung cancer

[Article in English, Portuguese]
Daniel R Almquist et al. J Bras Pneumol. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Strauss GM, Herndon JE, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. Nov. 2008;26(31):5043–5051. doi: 10.1200/JCO.2008.16.4855. - DOI - PMC - PubMed
    1. Douillard JY, De Lena RRM, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]) a randomised controlled trial. Lancet Oncol. Sep. 2006;7(9):719–727. doi: 10.1016/S1470-2045(06)70804-X. - DOI - PubMed
    1. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med. Jun. 2005;352(25):2589–2597. doi: 10.1056/NEJMoa043623. - DOI - PubMed
    1. Wakelee HA, Stephenson P, Keller SM, Wagner H, Herskovic A, Komaki R, et al. Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590 Lung Cancer. Jun. 2005;48(3):389–397. doi: 10.1016/j.lungcan.2004.11.007. - DOI - PubMed
    1. Scagliotti GV, Fossati R, Torri V, Crinò L, Giaccone G, Silvano G, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer J Natl Cancer Inst. Oct. 2003;95(19):1453–1461. doi: 10.1093/jnci/djg059. - DOI - PubMed

MeSH terms